Last reviewed · How we verify
PriorixTetra™
PriorixTetra is a live attenuated vaccine that stimulates the body's immune system to produce antibodies against measles, mumps, rubella, and varicella.
PriorixTetra is a live attenuated vaccine that stimulates the body's immune system to produce antibodies against measles, mumps, rubella, and varicella. Used for Measles, mumps, rubella, and varicella prevention in individuals 9 months of age and older.
At a glance
| Generic name | PriorixTetra™ |
|---|---|
| Also known as | MMRV vaccine (GSK208136) |
| Sponsor | GlaxoSmithKline |
| Drug class | live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened forms of the measles, mumps, rubella, and varicella viruses, which trigger an immune response and provide immunity against these diseases. This immune response is mediated by the production of antibodies and the activation of immune cells, such as T-cells and B-cells.
Approved indications
- Measles, mumps, rubella, and varicella prevention in individuals 9 months of age and older
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |